RS50348B - Farmaceutski oblik dronedarona za parenteralnu upotrebu - Google Patents

Farmaceutski oblik dronedarona za parenteralnu upotrebu

Info

Publication number
RS50348B
RS50348B YUP-465/03A YUP46503A RS50348B RS 50348 B RS50348 B RS 50348B YU P46503 A YUP46503 A YU P46503A RS 50348 B RS50348 B RS 50348B
Authority
RS
Serbia
Prior art keywords
parenteral administration
pharmaceutical
dronedarone
composition
dronedarone composition
Prior art date
Application number
YUP-465/03A
Other languages
English (en)
Inventor
Thierry Breul
Frédérique Bourriague-Seve
Original Assignee
Sanofi-Aventis,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis, filed Critical Sanofi-Aventis,
Publication of YU46503A publication Critical patent/YU46503A/sh
Publication of RS50348B publication Critical patent/RS50348B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Farmaceutski oblik za parenteralnu primenu, naznačen time što uključuje: -kao aktivnu supstancu dronedaron ili jednu od njegovih farmaceutski prihvatljivih soli, -fiziološki prihvatljiv puferski rastvor sposoban da održi pH rastvor između 3 i 5, -fiziološki prihvatljiv i u vodi rastvoran β-ciklodekstrinski derivat. Prijava sadrži još 18 patentnih zahteva.
YUP-465/03A 2000-12-11 2001-12-10 Farmaceutski oblik dronedarona za parenteralnu upotrebu RS50348B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0016071A FR2817750B1 (fr) 2000-12-11 2000-12-11 Composition pharmaceutique de dronedarone pour administration parenterale

Publications (2)

Publication Number Publication Date
YU46503A YU46503A (sh) 2006-08-17
RS50348B true RS50348B (sr) 2009-11-10

Family

ID=8857483

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-465/03A RS50348B (sr) 2000-12-11 2001-12-10 Farmaceutski oblik dronedarona za parenteralnu upotrebu

Country Status (31)

Country Link
US (1) US6939865B2 (sr)
EP (1) EP1343473B1 (sr)
JP (1) JP4399161B2 (sr)
KR (1) KR100849758B1 (sr)
CN (1) CN1235566C (sr)
AR (1) AR031649A1 (sr)
AT (1) ATE348599T1 (sr)
AU (2) AU2002217229B2 (sr)
BG (1) BG66187B1 (sr)
BR (1) BR0116060B1 (sr)
CA (1) CA2427375C (sr)
CZ (1) CZ297788B6 (sr)
DE (1) DE60125411T2 (sr)
EA (1) EA005314B1 (sr)
FR (1) FR2817750B1 (sr)
HK (1) HK1055906A1 (sr)
HU (1) HU229372B1 (sr)
IL (2) IL155428A0 (sr)
IS (1) IS2349B (sr)
MA (1) MA26969A1 (sr)
ME (2) MEP20408A (sr)
MX (1) MXPA03005221A (sr)
NO (1) NO332294B1 (sr)
NZ (1) NZ525661A (sr)
OA (1) OA12416A (sr)
PL (1) PL199846B1 (sr)
RS (1) RS50348B (sr)
SK (1) SK287115B6 (sr)
TW (1) TWI246926B (sr)
WO (1) WO2002047660A1 (sr)
ZA (1) ZA200303406B (sr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007215131A1 (en) * 2006-02-14 2007-08-23 Wyeth Aqueous pharmaceutical formulations of ERbeta selective ligands
GB0719180D0 (en) 2007-10-02 2007-11-14 Cambrex Karlskoga Ab New process
CA2721489A1 (en) * 2008-04-17 2009-12-03 Sanofi-Aventis Use of antiarrhythmic dronedarone to prevent cardiovascular hospitalization or sudden death due to cardiovascular causes
FR2930149B1 (fr) * 2008-04-17 2011-02-18 Sanofi Aventis Association de dronedarone avec au moins un diuretique, son application en therapeutique
EP2116239A1 (en) * 2008-04-29 2009-11-11 Sanofi-Aventis Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment
FR2959132A1 (fr) * 2010-04-22 2011-10-28 Sanofi Aventis Procedes pour l'evaluation et la reduction des risques
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
US20120005128A1 (en) * 2010-06-29 2012-01-05 Sanofi Methods for reducing the risk of an adverse dronedarone / calcium channel blockers interaction in a patient suffering from atrial fibrilation
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
CN102342907A (zh) 2010-07-30 2012-02-08 江苏恒瑞医药股份有限公司 决奈达隆固体分散体及其制备方法
KR20120094557A (ko) * 2011-02-01 2012-08-27 동아제약주식회사 피에이치 비의존적 용출양상을 갖는 부정맥치료제 제제
CN102908307A (zh) * 2011-08-03 2013-02-06 天津市嵩锐医药科技有限公司 供注射用盐酸决奈达隆药物组合物及其制备方法
EA201590199A1 (ru) * 2012-07-12 2015-05-29 Санофи Противоопухолевая композиция, содержащая соединение 1-(6-{[6-(4-фторфенил)[1,2,4]триазоло[4,3-b]пиридазин-3-ил]сульфанил}-1,3-бензотиазол-2-ил)-3-(2-морфолин-4-илэтил)мочевины
WO2022083636A1 (zh) * 2020-10-20 2022-04-28 上海博志研新药物技术有限公司 盐酸决奈达隆药物组合物、其制备方法及应用
CN115702878B (zh) * 2021-08-16 2024-05-10 上海云晟研新生物科技有限公司 盐酸决奈达隆注射组合物、其制备方法及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
FR2746013B1 (fr) * 1996-03-18 1998-05-29 Sanofi Sa Utilisation de composes antiarythmiques dans la prevention de la mortalite post infarctus
JP2004327321A (ja) * 2003-04-25 2004-11-18 Jst Mfg Co Ltd コネクタ

Also Published As

Publication number Publication date
CN1235566C (zh) 2006-01-11
HK1055906A1 (en) 2004-01-30
PL362788A1 (en) 2004-11-02
CA2427375A1 (fr) 2002-06-20
OA12416A (fr) 2006-04-18
ZA200303406B (en) 2004-05-03
JP4399161B2 (ja) 2010-01-13
BR0116060A (pt) 2004-03-02
US6939865B2 (en) 2005-09-06
SK287115B6 (sk) 2009-12-07
AR031649A1 (es) 2003-09-24
KR100849758B1 (ko) 2008-07-31
MXPA03005221A (es) 2004-03-26
CZ297788B6 (cs) 2007-03-28
IL155428A0 (en) 2003-11-23
PL199846B1 (pl) 2008-11-28
BR0116060B1 (pt) 2013-12-31
HU229372B1 (en) 2013-11-28
NO332294B1 (no) 2012-08-20
ATE348599T1 (de) 2007-01-15
NO20031958L (no) 2003-06-11
JP2004528277A (ja) 2004-09-16
CZ20031612A3 (cs) 2003-09-17
WO2002047660A1 (fr) 2002-06-20
DE60125411D1 (de) 2007-02-01
EP1343473B1 (fr) 2006-12-20
BG107748A (bg) 2004-03-31
FR2817750B1 (fr) 2003-02-21
IS6801A (is) 2003-04-30
IL155428A (en) 2007-10-31
HUP0500842A2 (hu) 2005-12-28
BG66187B1 (bg) 2011-12-30
EA005314B1 (ru) 2004-12-30
EA200300406A1 (ru) 2003-10-30
NO20031958D0 (no) 2003-04-29
FR2817750A1 (fr) 2002-06-14
AU1722902A (en) 2002-06-24
DE60125411T2 (de) 2007-10-11
KR20030060985A (ko) 2003-07-16
YU46503A (sh) 2006-08-17
AU2002217229B2 (en) 2006-05-18
IS2349B (is) 2008-04-15
TWI246926B (en) 2006-01-11
SK7262003A3 (en) 2004-02-03
EP1343473A1 (fr) 2003-09-17
ME00083B (me) 2010-10-10
NZ525661A (en) 2004-11-26
US20040044070A1 (en) 2004-03-04
MEP20408A (en) 2010-06-10
CN1479610A (zh) 2004-03-03
CA2427375C (fr) 2011-02-01
MA26969A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
RS50348B (sr) Farmaceutski oblik dronedarona za parenteralnu upotrebu
HRP20060240T3 (en) Intranasal formulation of rotigotine
BG106030A (en) Pharmaceutical composition
RS50360B (sr) Farmaceutske formulacije derivata platine
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
PL335571A1 (en) Stabilisation of acid-sensitive benzimidazoles by combining them with amino acids and cyclodextrins
LU91908I2 (fr) Telavancine, ou un de ses sels pharmaceutiquement acceptable, y compris l'hydrochlorure de telavancine (VIBATIV®)
BR9810495A (pt) Composição farmacêutica
ES2174083T3 (es) Composicion farmaceutica de amiodarona para administracion parenteral.
RS49723B (sr) Farmaceutska kompozicija koja sadrži entakapon ili nitekapon kao i umreženi derivat celuloze
NO20010863D0 (no) Nye orale formuleringer for 5-HT4-agonister eller - antagonister
IT1301968B1 (it) Derivati di eritromicina ad attivita' antibiotica
TR200301931T2 (tr) Saç gelişiminde 3 konumundaki siklosporin türevlerinin kullanılması
ATE376557T1 (de) Antimikrobielle sulfonamide-derivate von lipopeptidantibiotika
FR2793685B1 (fr) Compositions pharmaceutiques, destinees a l'administration par voie orale de phloroglucinol et leur preparation
ITMI20000293A0 (it) Derivati del 3,9-diazabiciclo [3.3.1]nonano ad attivita' analgesica
HRP20070081T5 (en) Nasal pharmaceutical composition of piribedil
EP1129712A4 (en) PREPARATIONS OF QUINOLINONE DERIVATIVES AND THEIR PRODUCTION METHOD
DE69912959D1 (de) Eythromycinderivat mit antibiotischer aktvität